Glutaredoxin 3 (GLRX3) confers a fusion oncogene-dependent vulnerability to Ewing sarcoma
Endrit Vinca, Anna C. Ehlers, Alina S. Ritter, David Obermeier, Cornelius Maximilian Funk, Florian H. Geyer, Melissa Schmucker, Jing Li, Malenka Zimmermann, A. Katharina Ceranski, Fabia Fuchslocher, Christina Mertens, Ruiyue Qiu, Martina Ulrike Muckenthaler, Alina Dahlhaus, , Shunya Ohmura
This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.
bioRxiv · Apr 24, 2024 · PreprintCancer Biology